Bonus BioGroup Ltd. (TASE: BONS)
Health Care · Biotechnology · IL
₪0.18
-16.89% today · -25.4% 1Y
Bonus BioGroup Ltd. (TASE: BONS) operates in the Biotechnology industry within the Health Care sector. The company is valued at $71.13M and employs 42 people.
Over the last twelve months the share price has lost 25.4%, trading between 0.18 and 0.61.
Tweenvest scores Bonus BioGroup Ltd. across four factors: quality 4/100. Its strongest factor is quality.
BONS price history
Not enough price history to draw a chart yet.
Key figures
- Market cap
- $71.13M
- Revenue (TTM)
- —
- P/E
- —
- EPS
- -0.02
- Dividend yield
- —
- Beta (5Y)
- 0.89
- 52-week high
- ₪0.61
- 52-week low
- ₪0.18
- Avg volume (3M)
- —
- Shares outstanding
- 1.17B
- Employees
- 42
- Next earnings
- —
About Bonus BioGroup Ltd.
Bonus BioGroup Ltd. is a clinical-stage biotechnology firm dedicated to creating therapeutic solutions through tissue engineering and cell-based therapies. Their flagship products include BonoFill, which is developed for regenerating bone tissue in maxillofacial and orthopedic applications, and MesenCure, aimed at treating COVID-19 patients suffering from pneumonia and acute respiratory distress syndrome (ARDS), as well as other life-threatening acute inflammatory illnesses. The company's innovation pipeline encompasses bone augmentation treatments for individuals with osteoporosis, cutting-edge nano-materials for drug delivery systems, and advancements in vascularized bone and soft tissue grafts. Originally known as Oceana Advanced Industries Ltd., the company was founded in 1981 and operates from Haifa, Israel.
- ISIN
- IL0004850116
- Founded
- 1981
- Listed since
- Aug 12, 2002
- Exchange
- The Tel-Aviv Stock Exchange
- Currency
- ILS
Other Biotechnology companies
| Company | Market cap | Price | Day |
|---|---|---|---|
| AbbVie Inc.NYSE: ABBV | $469.68B | $265.79 | +0.48% |
| Amgen Inc.NasdaqGS: AMGN | $239.09B | $442.24 | -0.36% |
| Gilead Sciences, Inc.NasdaqGS: GILD | $184.47B | $148.77 | +1.38% |
| Vertex Pharmaceuticals IncorporatedNasdaqGS: VRTX | $140.13B | $552.85 | +0.96% |
| Regeneron Pharmaceuticals, Inc.NasdaqGS: REGN | $83.24B | $833.56 | +0.61% |
| argenx SEENXTBR: ARGX | $64.17B | €879.20 | +1.74% |
| CSL LimitedASX: CSL | $59.49B | AU$173.64 | +2.68% |
| Moderna, Inc.NasdaqGS: MRNA | $55.45B | $158.83 | +14.36% |
Figures last refreshed Aug 18, 2026.